-
XW03 Peripheral Vein
-
XW030 Open
-
XW0300 Brexanolone
-
XW0300 Spesolimab Monoclonal Antibody
-
XW0301 Daratumumab and Hyaluronidase-fihj
-
XW0301 Eladocagene exuparvovec
-
XW0302 Bromelain-enriched Proteolytic Enzyme
-
XW0302 Nerinitide
-
XW0303 Durvalumab Antineoplastic
-
XW0303 Maribavir Anti-infective
-
XW0304 Teclistamab Antineoplastic
-
XW0305 Mosunetuzumab Antineoplastic
-
XW0305 Narsoplimab Monoclonal Antibody
-
XW0306 Afamitresgene Autoleucel Immunotherapy
-
XW0306 Lefamulin Anti-infective
-
XW0306 Terlipressin
-
XW0307 Coagulation Factor Xa, Inactivated
-
XW0307 Tabelecleucel Immunotherapy
-
XW0307 Trilaciclib
-
XW0308 Lurbinectedin
-
XW0308 Mineral-based Topical Hemostatic Agent
-
XW0308 Treosulfan
-
XW0308 Uridine Triacetate
-
XW0309 Ceftolozane/Tazobactam Anti-infective
-
XW0309 Inebilizumab-cdon
-
XW0309 Satralizumab-mwge
-
XW030A Cefiderocol Anti-infective
-
XW030A Ciltacabtagene Autoleucel
-
XW030B Amivantamab Monoclonal Antibody
-
XW030B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW030B Omadacycline Anti-infective
-
XW030C Eculizumab
-
XW030C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW030D Atezolizumab Antineoplastic
-
XW030D Engineered Allogeneic Thymus Tissue
-
XW030E Etesevimab Monoclonal Antibody
-
XW030E Remdesivir Anti-infective
-
XW030F Bamlanivimab Monoclonal Antibody
-
XW030F Other New Technology Therapeutic Substance
-
XW030G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW030G Plazomicin Anti-infective
-
XW030G REGN-COV2 Monoclonal Antibody
-
XW030G Sarilumab
-
XW030H Axicabtagene Ciloleucel Immunotherapy
-
XW030H Other New Technology Monoclonal Antibody
-
XW030H Synthetic Human Angiotensin II
-
XW030H Tocilizumab
-
XW030J Apalutamide Antineoplastic
-
XW030J Tisagenlecleucel Immunotherapy
-
XW030K Fosfomycin Anti-infective
-
XW030K Idecabtagene Vicleucel Immunotherapy
-
XW030K Leronlimab Monoclonal Antibody
-
XW030L CD24Fc Immunomodulator
-
XW030L Erdafitinib Antineoplastic
-
XW030L Lifileucel Immunotherapy
-
XW030M Baricitinib
-
XW030M Brexucabtagene Autoleucel Immunotherapy
-
XW030M Esketamine Hydrochloride
-
XW030N Lisocabtagene Maraleucel Immunotherapy
-
XW030N Meropenem-vaborbactam Anti-infective
-
XW030P Antibiotic-eluting Bone Void Filler
-
XW030Q Tagraxofusp-erzs Antineoplastic
-
XW030R Fostamatinib
-
XW030R Venetoclax Antineoplastic
-
XW030S COVID-19 Vaccine Dose 1
-
XW030S Iobenguane I-131 Antineoplastic
-
XW030T COVID-19 Vaccine Dose 2
-
XW030T Ruxolitinib
-
XW030U COVID-19 Vaccine
-
XW030U Imipenem-cilastatin-relebactam Anti-infective
-
XW030V COVID-19 Vaccine Dose 3
-
XW030V Gilteritinib Antineoplastic
-
XW030W Caplacizumab
-
XW030W COVID-19 Vaccine Booster
-
XW030X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW030X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW030Y Other New Technology Monoclonal Antibody
-
-
XW033 Percutaneous
-
XW0330 Brexanolone
-
XW0330 Spesolimab Monoclonal Antibody
-
XW0331 Daratumumab and Hyaluronidase-fihj
-
XW0331 Eladocagene exuparvovec
-
XW0332 Bromelain-enriched Proteolytic Enzyme
-
XW03326Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
-
XW0332 Nerinitide
-
XW03326Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
-
XW0333 Durvalumab Antineoplastic
-
XW03336Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
-
XW0333 Maribavir Anti-infective
-
XW03336Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
-
XW0334 Teclistamab Antineoplastic
-
XW0335 Mosunetuzumab Antineoplastic
-
XW0335 Narsoplimab Monoclonal Antibody
-
XW0336 Afamitresgene Autoleucel Immunotherapy
-
XW03366Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW03367Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
XW03368Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
-
-
XW0336 Lefamulin Anti-infective
-
XW03366Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW03367Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
XW03368Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
-
-
XW0336 Terlipressin
-
XW03366Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW03367Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
XW03368Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
-
-
XW0337 Coagulation Factor Xa, Inactivated
-
XW03372Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2
-
XW03377Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
XW03378Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
-
-
XW0337 Tabelecleucel Immunotherapy
-
XW03372Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2
-
XW03377Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
XW03378Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
-
-
XW0337 Trilaciclib
-
XW03372Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2
-
XW03377Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
XW03378Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
-
-
XW0338 Lurbinectedin
-
XW0338 Mineral-based Topical Hemostatic Agent
-
XW0338 Treosulfan
-
XW0338 Uridine Triacetate
-
XW0339 Ceftolozane/Tazobactam Anti-infective
-
XW0339 Inebilizumab-cdon
-
XW0339 Satralizumab-mwge
-
XW033A Cefiderocol Anti-infective
-
XW033A Ciltacabtagene Autoleucel
-
XW033B Amivantamab Monoclonal Antibody
-
XW033B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3
-
XW033B6Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW033B7Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW033B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3
-
XW033B6Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW033B7Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033B Omadacycline Anti-infective
-
XW033B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3
-
XW033B6Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW033B7Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033C Eculizumab
-
XW033C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW033D Atezolizumab Antineoplastic
-
XW033D6Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
-
XW033D Engineered Allogeneic Thymus Tissue
-
XW033D6Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
-
XW033E Etesevimab Monoclonal Antibody
-
XW033E Remdesivir Anti-infective
-
XW033F Bamlanivimab Monoclonal Antibody
-
XW033F3Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3
-
XW033F5Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
XW033F6Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
-
XW033F Other New Technology Therapeutic Substance
-
XW033F3Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3
-
XW033F5Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
XW033F6Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
-
XW033G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW033G4Introduction of Plazomicin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 4
-
XW033G5Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
XW033G6Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW033G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033G Plazomicin Anti-infective
-
XW033G4Introduction of Plazomicin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 4
-
XW033G5Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
XW033G6Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW033G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033G REGN-COV2 Monoclonal Antibody
-
XW033G4Introduction of Plazomicin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 4
-
XW033G5Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
XW033G6Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW033G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033G Sarilumab
-
XW033G4Introduction of Plazomicin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 4
-
XW033G5Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
XW033G6Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW033G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033H Axicabtagene Ciloleucel Immunotherapy
-
XW033H4Introduction of Synthetic Human Angiotensin II into Peripheral Vein, Percutaneous Approach, New Technology Group 4
-
XW033H5Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
XW033H6Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW033H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033H Other New Technology Monoclonal Antibody
-
XW033H4Introduction of Synthetic Human Angiotensin II into Peripheral Vein, Percutaneous Approach, New Technology Group 4
-
XW033H5Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
XW033H6Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW033H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033H Synthetic Human Angiotensin II
-
XW033H4Introduction of Synthetic Human Angiotensin II into Peripheral Vein, Percutaneous Approach, New Technology Group 4
-
XW033H5Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
XW033H6Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW033H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033H Tocilizumab
-
XW033H4Introduction of Synthetic Human Angiotensin II into Peripheral Vein, Percutaneous Approach, New Technology Group 4
-
XW033H5Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
XW033H6Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
-
XW033H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033J Apalutamide Antineoplastic
-
XW033J7Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033J Tisagenlecleucel Immunotherapy
-
XW033J7Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033K Fosfomycin Anti-infective
-
XW033K Idecabtagene Vicleucel Immunotherapy
-
XW033K Leronlimab Monoclonal Antibody
-
XW033L CD24Fc Immunomodulator
-
XW033L Erdafitinib Antineoplastic
-
XW033L Lifileucel Immunotherapy
-
XW033M Baricitinib
-
XW033M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033M Brexucabtagene Autoleucel Immunotherapy
-
XW033M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033M Esketamine Hydrochloride
-
XW033M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
-
-
XW033N Lisocabtagene Maraleucel Immunotherapy
-
XW033N Meropenem-vaborbactam Anti-infective
-
XW033P Antibiotic-eluting Bone Void Filler
-
XW033Q Tagraxofusp-erzs Antineoplastic
-
XW033Q5Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
-
XW033R Fostamatinib
-
XW033R Venetoclax Antineoplastic
-
XW033S COVID-19 Vaccine Dose 1
-
XW033S5Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
-
XW033S Iobenguane I-131 Antineoplastic
-
XW033S5Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
-
XW033T COVID-19 Vaccine Dose 2
-
XW033T Ruxolitinib
-
XW033U COVID-19 Vaccine
-
XW033U5Introduction of Imipenem-cilastatin-relebactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
-
XW033U Imipenem-cilastatin-relebactam Anti-infective
-
XW033U5Introduction of Imipenem-cilastatin-relebactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
-
XW033V COVID-19 Vaccine Dose 3
-
XW033V Gilteritinib Antineoplastic
-
XW033W Caplacizumab
-
XW033W5Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
-
XW033W COVID-19 Vaccine Booster
-
XW033W5Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
-
-
XW033X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW033X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW033Y Other New Technology Monoclonal Antibody
-
-
XW037 Via Natural or Artificial Opening
-
XW0370 Brexanolone
-
XW0370 Spesolimab Monoclonal Antibody
-
XW0371 Daratumumab and Hyaluronidase-fihj
-
XW0371 Eladocagene exuparvovec
-
XW0372 Bromelain-enriched Proteolytic Enzyme
-
XW0372 Nerinitide
-
XW0373 Durvalumab Antineoplastic
-
XW0373 Maribavir Anti-infective
-
XW0374 Teclistamab Antineoplastic
-
XW0375 Mosunetuzumab Antineoplastic
-
XW0375 Narsoplimab Monoclonal Antibody
-
XW0376 Afamitresgene Autoleucel Immunotherapy
-
XW0376 Lefamulin Anti-infective
-
XW0376 Terlipressin
-
XW0377 Coagulation Factor Xa, Inactivated
-
XW0377 Tabelecleucel Immunotherapy
-
XW0377 Trilaciclib
-
XW0378 Lurbinectedin
-
XW0378 Mineral-based Topical Hemostatic Agent
-
XW0378 Treosulfan
-
XW0378 Uridine Triacetate
-
XW0379 Ceftolozane/Tazobactam Anti-infective
-
XW0379 Inebilizumab-cdon
-
XW0379 Satralizumab-mwge
-
XW037A Cefiderocol Anti-infective
-
XW037A Ciltacabtagene Autoleucel
-
XW037B Amivantamab Monoclonal Antibody
-
XW037B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW037B Omadacycline Anti-infective
-
XW037C Eculizumab
-
XW037C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW037D Atezolizumab Antineoplastic
-
XW037D Engineered Allogeneic Thymus Tissue
-
XW037E Etesevimab Monoclonal Antibody
-
XW037E Remdesivir Anti-infective
-
XW037F Bamlanivimab Monoclonal Antibody
-
XW037F Other New Technology Therapeutic Substance
-
XW037G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW037G Plazomicin Anti-infective
-
XW037G REGN-COV2 Monoclonal Antibody
-
XW037G Sarilumab
-
XW037H Axicabtagene Ciloleucel Immunotherapy
-
XW037H Other New Technology Monoclonal Antibody
-
XW037H Synthetic Human Angiotensin II
-
XW037H Tocilizumab
-
XW037J Apalutamide Antineoplastic
-
XW037J Tisagenlecleucel Immunotherapy
-
XW037K Fosfomycin Anti-infective
-
XW037K Idecabtagene Vicleucel Immunotherapy
-
XW037K Leronlimab Monoclonal Antibody
-
XW037L CD24Fc Immunomodulator
-
XW037L Erdafitinib Antineoplastic
-
XW037L Lifileucel Immunotherapy
-
XW037M Baricitinib
-
XW037M Brexucabtagene Autoleucel Immunotherapy
-
XW037M Esketamine Hydrochloride
-
XW037N Lisocabtagene Maraleucel Immunotherapy
-
XW037N Meropenem-vaborbactam Anti-infective
-
XW037P Antibiotic-eluting Bone Void Filler
-
XW037Q Tagraxofusp-erzs Antineoplastic
-
XW037R Fostamatinib
-
XW037R Venetoclax Antineoplastic
-
XW037S COVID-19 Vaccine Dose 1
-
XW037S Iobenguane I-131 Antineoplastic
-
XW037T COVID-19 Vaccine Dose 2
-
XW037T Ruxolitinib
-
XW037U COVID-19 Vaccine
-
XW037U Imipenem-cilastatin-relebactam Anti-infective
-
XW037V COVID-19 Vaccine Dose 3
-
XW037V Gilteritinib Antineoplastic
-
XW037W Caplacizumab
-
XW037W COVID-19 Vaccine Booster
-
XW037X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW037X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW037Y Other New Technology Monoclonal Antibody
-
-
XW038 Via Natural or Artificial Opening Endoscopic
-
XW0380 Brexanolone
-
XW0380 Spesolimab Monoclonal Antibody
-
XW0381 Daratumumab and Hyaluronidase-fihj
-
XW0381 Eladocagene exuparvovec
-
XW0382 Bromelain-enriched Proteolytic Enzyme
-
XW0382 Nerinitide
-
XW0383 Durvalumab Antineoplastic
-
XW0383 Maribavir Anti-infective
-
XW0384 Teclistamab Antineoplastic
-
XW0385 Mosunetuzumab Antineoplastic
-
XW0385 Narsoplimab Monoclonal Antibody
-
XW0386 Afamitresgene Autoleucel Immunotherapy
-
XW0386 Lefamulin Anti-infective
-
XW0386 Terlipressin
-
XW0387 Coagulation Factor Xa, Inactivated
-
XW0387 Tabelecleucel Immunotherapy
-
XW0387 Trilaciclib
-
XW0388 Lurbinectedin
-
XW0388 Mineral-based Topical Hemostatic Agent
-
XW0388 Treosulfan
-
XW0388 Uridine Triacetate
-
XW0389 Ceftolozane/Tazobactam Anti-infective
-
XW0389 Inebilizumab-cdon
-
XW0389 Satralizumab-mwge
-
XW038A Cefiderocol Anti-infective
-
XW038A Ciltacabtagene Autoleucel
-
XW038B Amivantamab Monoclonal Antibody
-
XW038B Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW038B Omadacycline Anti-infective
-
XW038C Eculizumab
-
XW038C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW038D Atezolizumab Antineoplastic
-
XW038D Engineered Allogeneic Thymus Tissue
-
XW038E Etesevimab Monoclonal Antibody
-
XW038E Remdesivir Anti-infective
-
XW038F Bamlanivimab Monoclonal Antibody
-
XW038F Other New Technology Therapeutic Substance
-
XW038G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW038G Plazomicin Anti-infective
-
XW038G REGN-COV2 Monoclonal Antibody
-
XW038G Sarilumab
-
XW038H Axicabtagene Ciloleucel Immunotherapy
-
XW038H Other New Technology Monoclonal Antibody
-
XW038H Synthetic Human Angiotensin II
-
XW038H Tocilizumab
-
XW038J Apalutamide Antineoplastic
-
XW038J Tisagenlecleucel Immunotherapy
-
XW038K Fosfomycin Anti-infective
-
XW038K Idecabtagene Vicleucel Immunotherapy
-
XW038K Leronlimab Monoclonal Antibody
-
XW038L CD24Fc Immunomodulator
-
XW038L Erdafitinib Antineoplastic
-
XW038L Lifileucel Immunotherapy
-
XW038M Baricitinib
-
XW038M Brexucabtagene Autoleucel Immunotherapy
-
XW038M Esketamine Hydrochloride
-
XW038N Lisocabtagene Maraleucel Immunotherapy
-
XW038N Meropenem-vaborbactam Anti-infective
-
XW038P Antibiotic-eluting Bone Void Filler
-
XW038Q Tagraxofusp-erzs Antineoplastic
-
XW038R Fostamatinib
-
XW038R Venetoclax Antineoplastic
-
XW038S COVID-19 Vaccine Dose 1
-
XW038S Iobenguane I-131 Antineoplastic
-
XW038T COVID-19 Vaccine Dose 2
-
XW038T Ruxolitinib
-
XW038U COVID-19 Vaccine
-
XW038U Imipenem-cilastatin-relebactam Anti-infective
-
XW038V COVID-19 Vaccine Dose 3
-
XW038V Gilteritinib Antineoplastic
-
XW038W Caplacizumab
-
XW038W COVID-19 Vaccine Booster
-
XW038X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW038X Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW038Y Other New Technology Monoclonal Antibody
-
-
XW03X External
-
XW03X0 Brexanolone
-
XW03X0 Spesolimab Monoclonal Antibody
-
XW03X1 Daratumumab and Hyaluronidase-fihj
-
XW03X1 Eladocagene exuparvovec
-
XW03X2 Bromelain-enriched Proteolytic Enzyme
-
XW03X2 Nerinitide
-
XW03X3 Durvalumab Antineoplastic
-
XW03X3 Maribavir Anti-infective
-
XW03X4 Teclistamab Antineoplastic
-
XW03X5 Mosunetuzumab Antineoplastic
-
XW03X5 Narsoplimab Monoclonal Antibody
-
XW03X6 Afamitresgene Autoleucel Immunotherapy
-
XW03X6 Lefamulin Anti-infective
-
XW03X6 Terlipressin
-
XW03X7 Coagulation Factor Xa, Inactivated
-
XW03X7 Tabelecleucel Immunotherapy
-
XW03X7 Trilaciclib
-
XW03X8 Lurbinectedin
-
XW03X8 Mineral-based Topical Hemostatic Agent
-
XW03X8 Treosulfan
-
XW03X8 Uridine Triacetate
-
XW03X9 Ceftolozane/Tazobactam Anti-infective
-
XW03X9 Inebilizumab-cdon
-
XW03X9 Satralizumab-mwge
-
XW03XA Cefiderocol Anti-infective
-
XW03XA Ciltacabtagene Autoleucel
-
XW03XB Amivantamab Monoclonal Antibody
-
XW03XB Cytarabine and Daunorubicin Liposome Antineoplastic
-
XW03XB Omadacycline Anti-infective
-
XW03XC Eculizumab
-
XW03XC Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous
-
XW03XD Atezolizumab Antineoplastic
-
XW03XD Engineered Allogeneic Thymus Tissue
-
XW03XE Etesevimab Monoclonal Antibody
-
XW03XE Remdesivir Anti-infective
-
XW03XF Bamlanivimab Monoclonal Antibody
-
XW03XF Other New Technology Therapeutic Substance
-
XW03XG Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic
-
XW03XG Plazomicin Anti-infective
-
XW03XG REGN-COV2 Monoclonal Antibody
-
XW03XG Sarilumab
-
XW03XH Axicabtagene Ciloleucel Immunotherapy
-
XW03XH Other New Technology Monoclonal Antibody
-
XW03XH Synthetic Human Angiotensin II
-
XW03XH Tocilizumab
-
XW03XJ Apalutamide Antineoplastic
-
XW03XJ Tisagenlecleucel Immunotherapy
-
XW03XK Fosfomycin Anti-infective
-
XW03XK Idecabtagene Vicleucel Immunotherapy
-
XW03XK Leronlimab Monoclonal Antibody
-
XW03XL CD24Fc Immunomodulator
-
XW03XL Erdafitinib Antineoplastic
-
XW03XL Lifileucel Immunotherapy
-
XW03XM Baricitinib
-
XW03XM Brexucabtagene Autoleucel Immunotherapy
-
XW03XM Esketamine Hydrochloride
-
XW03XN Lisocabtagene Maraleucel Immunotherapy
-
XW03XN Meropenem-vaborbactam Anti-infective
-
XW03XP Antibiotic-eluting Bone Void Filler
-
XW03XQ Tagraxofusp-erzs Antineoplastic
-
XW03XR Fostamatinib
-
XW03XR Venetoclax Antineoplastic
-
XW03XS COVID-19 Vaccine Dose 1
-
XW03XS Iobenguane I-131 Antineoplastic
-
XW03XT COVID-19 Vaccine Dose 2
-
XW03XT Ruxolitinib
-
XW03XU COVID-19 Vaccine
-
XW03XU Imipenem-cilastatin-relebactam Anti-infective
-
XW03XV COVID-19 Vaccine Dose 3
-
XW03XV Gilteritinib Antineoplastic
-
XW03XW Caplacizumab
-
XW03XW COVID-19 Vaccine Booster
-
XW03XX Broad Consortium Microbiota-based Live Biotherapeutic Suspension
-
XW03XX Tixagevimab and Cilgavimab Monoclonal Antibody
-
XW03XY Other New Technology Monoclonal Antibody
-
-